Protalix BioTherapeutics Eligible for $20 Million Milestone Payment
By Chris Wack
Protalix BioTherapeutics said Thursday that it is eligible to receive a $20 million milestone payment from its commercial partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group.
The company said the milestone payment was triggered by the approval by the U.S. Food and Drug Administration of Elfabrio pegunigalsidase alfa-iwxj for the treatment of adult patients with Fabry disease.
The FDA's approval was announced May 10, 2023, and the milestone payment is payable within 30 days of the FDA approval date.
In July 2018, the company entered into an exclusive license and supply agreement with Chiesi Farmaceutici, where it granted Chiesi an exclusive license to commercialize pegunigalsidase alfa in the U.S.
Protalix has already received a total of $95 million in upfront payments and to cover development costs.
On a proforma basis, including the receipt of the $20 million milestone payment, Protalix has cash and cash equivalents of $51.6 million as of Thursday.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 18, 2023 07:13 ET (11:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth